6 unknown. 6 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Unknown 6 |
| Phase 1 | 2 | Unknown 2 |
| Phase 3 | 1 | Unknown 1 |
Follow Immune Checkpoint Inhibitors: new trials by email Literature Review of Immune Checkpoint Inhibitors trials Research Report on Immune Checkpoint Inhibitors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cadonilimab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma Cadonilimab, Gemcitabine, Cisplatin - Nasopharyngeal Carcinoma, Immune Checkpoint Inhibitors | Phase 1 / Phase 2 | Unknown | Guangxi Medical University | 20 | 2023-08-01 | 2023-06-12 |
| Efficacy and Safety of SBRT Combined With Cardonilizumab and Lenvastinib in the Treatment of Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus Cadonilimab, Stereotactic radiotherapy, Renvatinib - Hepatocellular Carcinoma Non-resectable, Portal Vein Tumor Thrombus | Phase 1 / Phase 2 | Unknown | First Affiliated Hospital of Guangxi Medical University | 30 | 2023-02-02 | 2023-09-15 |
| The Efficacy of Chemotherapy Combined With Immunocheckpoint Inhibitors in Advanced Biliary Malignancies Gemcitabine-based chemotherapy regimen combined with immunocheckpoint inhibitors - Gemcitabine, Biliary Tract Cancer | Phase 2 / Phase 3 | Unknown | First People's Hospital of Hangzhou | 50 | 2022-08-01 | 2022-08-04 |
| Tislelizumab and Radiotherapy for Recurrent Cervical Cancer Tislelizumab plus radiotherapy - Recurrent Cervical Carcinoma, Metastatic Cervical Carcinoma | Phase 2 | Unknown | Lei Li | 58 | 2022-03-27 | 2022-04-11 |
| Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy: Multi-Center Trial Anti-PD-1 antibody camrelizumab, Albumin-bound paclitaxel - Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma | Phase 2 | Unknown | Lei Li | 122 | 2022-03-13 | 2022-03-22 |
| A Study of Camrelizumab Combined Apatinib in Hepatocellular Carcinoma Previously Treated With Immune Checkpoint Inhibitors (ICIs). Camrelizumab combined Apatinib regimen - Hepatocellular Carcinoma, Immune Checkpoint Inhibitors | Phase 2 | Unknown | Hunan Cancer Hospital | 40 | 2021-02-03 | 2021-04-01 |
Carcinoma, Hepatocellular (2) · Uterine Cervical Neoplasms (2) · Biliary Tract Neoplasms (1) · Nasopharyngeal Carcinoma (1)
Neoplasms (6) · Neoplasms by Site (6) · Carcinoma (3) · Digestive System Diseases (3) · Digestive System Neoplasms (3) · Neoplasms by Histologic Type (3) · Neoplasms, Glandular and Epithelial (3) · Adenocarcinoma (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Genital Diseases (2) · Genital Diseases, Female (2) · Genital Neoplasms, Female (2) · Liver Diseases (2) · Liver Neoplasms (2)
Albumin-Bound Paclitaxel (1) · Cisplatin (1) · Gemcitabine (1) · Radiosurgery (1) · Radiotherapy (1) · tislelizumab (1)
Lei Li (2) · First Affiliated Hospital of Guangxi Medical University (1) · First People's Hospital of Hangzhou (1) · Guangxi Medical University (1) · Hunan Cancer Hospital (1)
China (5)
Lei Li, M.D. (2)